
Chinese General Practice ›› 2022, Vol. 25 ›› Issue (06): 714-718.DOI: 10.12114/j.issn.1007-9572.2021.02.091
• Article • Previous Articles Next Articles
Overall and Sex-specific Associations between Ratio of Monocyte to High-density Lipoprotein Cholesterol and Hyperuricemia Prevalence
1.Department of General Practice,Shanghai Pudong New Area Laogang Community Health Center,Shanghai 201302,China
2.Cardiovascular Department,the Sixth People's Hospital Affiliated to Shanghai Jiao Tong University,Shanghai 200233,China
*Corresponding author:CHEN Zhong,Chief physician;E-mail:zhongchen7498@hotmail.com
Received:2021-07-03
Revised:2021-10-12
Published:2022-02-20
Online:2022-01-25
通讯作者:
陈忠
基金资助:CLC Number:
WANG Yanping, WU Meihua, YANG Sheng, CHEN Zhong.
Overall and Sex-specific Associations between Ratio of Monocyte to High-density Lipoprotein Cholesterol and Hyperuricemia Prevalence [J]. Chinese General Practice, 2022, 25(06): 714-718.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2021.02.091
| 一般资料 | 男性(n=5 498) | 女性(n=6 807) | ||||||
|---|---|---|---|---|---|---|---|---|
| 非HUA者(n=4 524) | HUA患者(n=974) | 检验统计量值 | P值 | 非HUA者(n=5 833) | HUA患者(n=974) | 检验统计量值 | P值 | |
年龄( ±s,岁) | 64.8±9.0 | 65.4±9.6 | 1.865a | 0.066 | 64.7±9.3 | 68.5±10.4 | 11.599a | <0.001 |
SBP( ±s,mm Hg) | 147±20 | 149±20 | 2.879a | 0.004 | 150±20 | 155±21 | 6.179a | <0.001 |
DBP( ±s,mm Hg) | 84±11 | 85±11 | 2.843a | 0.004 | 82±11 | 83±11 | 3.164a | 0.002 |
BMI( ±s,kg/m2) | 24.1±3.2 | 25.7±3.2 | 14.155a | <0.001 | 24.3±3.5 | 26.2±3.7 | 15.211a | <0.001 |
| MONO〔M(QR),×109/L〕 | 0.43(0.20) | 0.45(0.19) | 4.073b | <0.001 | 0.36(0.15) | 0.41(0.17) | 11.574b | <0.001 |
WBC( ±s,×109/L) | 6.10±1.51 | 6.59±1.55 | 9.143a | <0.001 | 6.01±1.47 | 6.55±1.61 | 10.464a | <0.001 |
FPG( ±s,mmol/L) | 5.18±1.66 | 5.12±1.26 | 1.064a | 0.287 | 5.21±1.58 | 5.50±1.63 | 5.278a | <0.001 |
| ALT〔M(QR),U/L〕 | 22.10(16.50) | 27.35(19.93) | 9.968b | <0.001 | 20.9(15.20) | 25.7(20.30) | 10.401b | <0.001 |
| AST〔M(QR),U/L〕 | 24.60(10.20) | 26.60(11.75) | 7.703b | <0.001 | 24.8(10.10) | 26.9(12.95) | 7.753b | <0.001 |
BUN( ±s,mmol/L) | 5.84±1.57 | 6.20±1.88 | 6.256a | <0.001 | 5.67±1.59 | 6.44±2.11 | 13.286a | <0.001 |
eGFR〔 ±s,ml·min-1·(1.73 m2)-1〕 | 112.08±26.45 | 94.29±24.16 | 19.326a | <0.001 | 107.90±23.22 | 88.51±25.33 | 23.804a | <0.001 |
| LDL-C〔M(QR),mmol/L〕 | 2.82(0.92) | 2.88(1.04) | 2.840b | 0.004 | 3.06(0.96) | 3.19(1.17) | 3.858b | <0.001 |
| TG〔M(QR),mmol/L〕 | 1.17(6.96) | 1.69(1.44) | 17.096b | <0.001 | 1.32(0.98) | 1.85(1.37) | 18.923b | <0.001 |
| HDL-C〔M(QR),mmol/L〕 | 1.52(0.49) | 1.46(0.46) | 6.087b | <0.001 | 1.64(0.51) | 1.57(0.47) | 5.649b | <0.001 |
| TC〔M(QR),mmol/L〕 | 5.00(1.30) | 5.07(1.39) | 1.485b | 0.136 | 5.38(1.35) | 5.53(1.61) | 4.034b | <0.001 |
| 脂肪肝〔n(%)〕 | 1 247(27.6) | 406(41.7) | 75.992 | <0.001 | 2 534(43.4) | 637(65.4) | 161.722 | <0.001 |
| T2DM〔n(%)〕 | 703(15.5) | 114(11.7) | 9.317 | 0.003 | 974(16.7) | 224(23.0) | 22.842 | <0.001 |
| 高血压〔n(%)〕 | 1 817(40.2) | 561(57.6) | 99.246 | <0.001 | 2 499(42.8) | 642(65.9) | 178.768 | <0.001 |
| MHR〔M(QR)〕 | 0.28(0.16) | 0.32(0.17) | 7.539b | <0.001 | 0.22(0.12) | 0.26(0.15) | 11.856b | <0.001 |
Table 1 Comparison of general characteristics in physical examinees with and without HUA by sex
| 一般资料 | 男性(n=5 498) | 女性(n=6 807) | ||||||
|---|---|---|---|---|---|---|---|---|
| 非HUA者(n=4 524) | HUA患者(n=974) | 检验统计量值 | P值 | 非HUA者(n=5 833) | HUA患者(n=974) | 检验统计量值 | P值 | |
年龄( ±s,岁) | 64.8±9.0 | 65.4±9.6 | 1.865a | 0.066 | 64.7±9.3 | 68.5±10.4 | 11.599a | <0.001 |
SBP( ±s,mm Hg) | 147±20 | 149±20 | 2.879a | 0.004 | 150±20 | 155±21 | 6.179a | <0.001 |
DBP( ±s,mm Hg) | 84±11 | 85±11 | 2.843a | 0.004 | 82±11 | 83±11 | 3.164a | 0.002 |
BMI( ±s,kg/m2) | 24.1±3.2 | 25.7±3.2 | 14.155a | <0.001 | 24.3±3.5 | 26.2±3.7 | 15.211a | <0.001 |
| MONO〔M(QR),×109/L〕 | 0.43(0.20) | 0.45(0.19) | 4.073b | <0.001 | 0.36(0.15) | 0.41(0.17) | 11.574b | <0.001 |
WBC( ±s,×109/L) | 6.10±1.51 | 6.59±1.55 | 9.143a | <0.001 | 6.01±1.47 | 6.55±1.61 | 10.464a | <0.001 |
FPG( ±s,mmol/L) | 5.18±1.66 | 5.12±1.26 | 1.064a | 0.287 | 5.21±1.58 | 5.50±1.63 | 5.278a | <0.001 |
| ALT〔M(QR),U/L〕 | 22.10(16.50) | 27.35(19.93) | 9.968b | <0.001 | 20.9(15.20) | 25.7(20.30) | 10.401b | <0.001 |
| AST〔M(QR),U/L〕 | 24.60(10.20) | 26.60(11.75) | 7.703b | <0.001 | 24.8(10.10) | 26.9(12.95) | 7.753b | <0.001 |
BUN( ±s,mmol/L) | 5.84±1.57 | 6.20±1.88 | 6.256a | <0.001 | 5.67±1.59 | 6.44±2.11 | 13.286a | <0.001 |
eGFR〔 ±s,ml·min-1·(1.73 m2)-1〕 | 112.08±26.45 | 94.29±24.16 | 19.326a | <0.001 | 107.90±23.22 | 88.51±25.33 | 23.804a | <0.001 |
| LDL-C〔M(QR),mmol/L〕 | 2.82(0.92) | 2.88(1.04) | 2.840b | 0.004 | 3.06(0.96) | 3.19(1.17) | 3.858b | <0.001 |
| TG〔M(QR),mmol/L〕 | 1.17(6.96) | 1.69(1.44) | 17.096b | <0.001 | 1.32(0.98) | 1.85(1.37) | 18.923b | <0.001 |
| HDL-C〔M(QR),mmol/L〕 | 1.52(0.49) | 1.46(0.46) | 6.087b | <0.001 | 1.64(0.51) | 1.57(0.47) | 5.649b | <0.001 |
| TC〔M(QR),mmol/L〕 | 5.00(1.30) | 5.07(1.39) | 1.485b | 0.136 | 5.38(1.35) | 5.53(1.61) | 4.034b | <0.001 |
| 脂肪肝〔n(%)〕 | 1 247(27.6) | 406(41.7) | 75.992 | <0.001 | 2 534(43.4) | 637(65.4) | 161.722 | <0.001 |
| T2DM〔n(%)〕 | 703(15.5) | 114(11.7) | 9.317 | 0.003 | 974(16.7) | 224(23.0) | 22.842 | <0.001 |
| 高血压〔n(%)〕 | 1 817(40.2) | 561(57.6) | 99.246 | <0.001 | 2 499(42.8) | 642(65.9) | 178.768 | <0.001 |
| MHR〔M(QR)〕 | 0.28(0.16) | 0.32(0.17) | 7.539b | <0.001 | 0.22(0.12) | 0.26(0.15) | 11.856b | <0.001 |
| 因素 | 男性(n=5 498) | 女性(n=6 807) | ||
|---|---|---|---|---|
| r(rs)值 | P值 | r(rs)值 | P值 | |
| 年龄 | 0.011 | 0.395 | 0.163 | <0.001 |
| SBP | 0.052 | <0.001 | 0.092 | <0.001 |
| DBP | 0.071 | <0.001 | 0.046 | <0.001 |
| BMI | 0.210 | <0.001 | 0.260 | <0.001 |
| MONO | 0.098a | <0.001 | 0.182a | <0.001 |
| WBC | 0.073 | <0.001 | 0.160 | <0.001 |
| FPG | -0.032 | 0.018 | 0.094 | <0.001 |
| ALT | 0.160a | <0.001 | 0.198a | <0.001 |
| AST | 0.129a | <0.001 | 0.163a | <0.001 |
| BUN | 0.119 | <0.001 | 0.217 | <0.001 |
| eGFR | -0.382 | <0.001 | -0.371 | <0.001 |
| LDL-C | 0.091a | <0.001 | 0.090a | <0.001 |
| TG | 0.221a | <0.001 | 0.276a | <0.001 |
| HDL-C | -0.092a | <0.001 | -0.082a | <0.001 |
| TC | 0.062a | <0.001 | 0.072a | <0.001 |
| MHR | 0.122a | <0.001 | 0.185a | <0.001 |
Table 2 Correlation analysis of serum uric acid and other factors in physical examinees by sex
| 因素 | 男性(n=5 498) | 女性(n=6 807) | ||
|---|---|---|---|---|
| r(rs)值 | P值 | r(rs)值 | P值 | |
| 年龄 | 0.011 | 0.395 | 0.163 | <0.001 |
| SBP | 0.052 | <0.001 | 0.092 | <0.001 |
| DBP | 0.071 | <0.001 | 0.046 | <0.001 |
| BMI | 0.210 | <0.001 | 0.260 | <0.001 |
| MONO | 0.098a | <0.001 | 0.182a | <0.001 |
| WBC | 0.073 | <0.001 | 0.160 | <0.001 |
| FPG | -0.032 | 0.018 | 0.094 | <0.001 |
| ALT | 0.160a | <0.001 | 0.198a | <0.001 |
| AST | 0.129a | <0.001 | 0.163a | <0.001 |
| BUN | 0.119 | <0.001 | 0.217 | <0.001 |
| eGFR | -0.382 | <0.001 | -0.371 | <0.001 |
| LDL-C | 0.091a | <0.001 | 0.090a | <0.001 |
| TG | 0.221a | <0.001 | 0.276a | <0.001 |
| HDL-C | -0.092a | <0.001 | -0.082a | <0.001 |
| TC | 0.062a | <0.001 | 0.072a | <0.001 |
| MHR | 0.122a | <0.001 | 0.185a | <0.001 |
| 变量 | 赋值 |
|---|---|
| HUA | 否=0,是=1 |
| MONO | 连续变量 |
| MHR | 连续变量 |
| MHR四分位数(男性) | Q1=1,Q2=2,Q3=3,Q4=4 |
| MHR四分位数(女性) | Q1=1,Q2=2,Q3=3,Q4=4 |
| 年龄 | 连续变量 |
| BMI | 连续变量 |
| eGFR | 连续变量 |
| LDL-C | 连续变量 |
| TG | 连续变量 |
| 脂肪肝 | 否=0,是=1 |
| T2DM | 否=0,是=1 |
| 高血压 | 否=0,是=1 |
Table 3 Assignment for monocytes,MHR and other factors possibly associated with HUA in physical examinees analyzed using multivariate Logistic regression analysis
| 变量 | 赋值 |
|---|---|
| HUA | 否=0,是=1 |
| MONO | 连续变量 |
| MHR | 连续变量 |
| MHR四分位数(男性) | Q1=1,Q2=2,Q3=3,Q4=4 |
| MHR四分位数(女性) | Q1=1,Q2=2,Q3=3,Q4=4 |
| 年龄 | 连续变量 |
| BMI | 连续变量 |
| eGFR | 连续变量 |
| LDL-C | 连续变量 |
| TG | 连续变量 |
| 脂肪肝 | 否=0,是=1 |
| T2DM | 否=0,是=1 |
| 高血压 | 否=0,是=1 |
| 变量 | 男性 | 女性 | ||
|---|---|---|---|---|
| OR(95%CI) | P值 | OR(95%CI) | P值 | |
| 模型1 | 2.841(1.859,4.341) | <0.001 | 11.479(6.924,19.030) | <0.001 |
| 模型2 | 2.207(1.429,3.410) | <0.001 | 6.711(3.990,11.287) | <0.001 |
| 模型3 | 2.010(1.265,3.194) | 0.003 | 5.427(3.059,9.627) | <0.001 |
Table 4 Multivariate Logistic regression analysis of association of monocytes and HUA in male and female physical examinees
| 变量 | 男性 | 女性 | ||
|---|---|---|---|---|
| OR(95%CI) | P值 | OR(95%CI) | P值 | |
| 模型1 | 2.841(1.859,4.341) | <0.001 | 11.479(6.924,19.030) | <0.001 |
| 模型2 | 2.207(1.429,3.410) | <0.001 | 6.711(3.990,11.287) | <0.001 |
| 模型3 | 2.010(1.265,3.194) | 0.003 | 5.427(3.059,9.627) | <0.001 |
| 变量 | 模型1 | 模型2 | 模型3 | |||||
|---|---|---|---|---|---|---|---|---|
| OR(95%CI) | P值 | OR(95%CI) | P值 | OR(95%CI) | P值 | |||
| 男性 | ||||||||
| MHR | 5.319(3.374,8.383) | <0.001 | 3.495(2.164,5.646) | <0.001 | 1.918(1.111,3.313) | 0.019 | ||
| MHR四分位数 | ||||||||
| Q1 | 1.000 | - | 1.000 | - | 1.000 | - | ||
| Q2 | 1.154(0.927,1.435) | 0.200 | 1.114(0.892,1.391) | 0.341 | 1.016(0.804,1.283) | 0.896 | ||
| Q3 | 1.535(1.247,1.890) | <0.001 | 1.366(1.103,1.690) | 0.004 | 1.121(0.892,1.409) | 0.326 | ||
| Q4 | 2.010(1.644,2.458) | <0.001 | 1.668(1.353,2.057) | <0.001 | 1.306(1.037,1.645) | 0.023 | ||
| 女性 | ||||||||
| MHR | 36.791(20.816,65.025) | <0.001 | 9.120(4.976,16.714) | <0.001 | 6.073(2.984,12.358) | <0.001 | ||
| MHR四分位数 | ||||||||
| Q1 | 1.000 | - | 1.000 | - | 1.000 | - | ||
| Q2 | 1.401(1.119,1.753) | 0.003 | 1.234(0.981,1.552) | 0.072 | 1.206(0.946,1.537) | 0.130 | ||
| Q3 | 1.792(1.457,2.203) | <0.001 | 1.344(1.085,1.664) | 0.007 | 1.297(1.032,1.631) | 0.026 | ||
| Q4 | 2.954(2.418,3.610) | <0.001 | 1.903(1.542,2.348) | <0.001 | 1.683(1.329,2.130) | <0.001 | ||
Table 5 Multivariate Logistic regression analysis of the association of MHR and HUA in male and female physical examinees
| 变量 | 模型1 | 模型2 | 模型3 | |||||
|---|---|---|---|---|---|---|---|---|
| OR(95%CI) | P值 | OR(95%CI) | P值 | OR(95%CI) | P值 | |||
| 男性 | ||||||||
| MHR | 5.319(3.374,8.383) | <0.001 | 3.495(2.164,5.646) | <0.001 | 1.918(1.111,3.313) | 0.019 | ||
| MHR四分位数 | ||||||||
| Q1 | 1.000 | - | 1.000 | - | 1.000 | - | ||
| Q2 | 1.154(0.927,1.435) | 0.200 | 1.114(0.892,1.391) | 0.341 | 1.016(0.804,1.283) | 0.896 | ||
| Q3 | 1.535(1.247,1.890) | <0.001 | 1.366(1.103,1.690) | 0.004 | 1.121(0.892,1.409) | 0.326 | ||
| Q4 | 2.010(1.644,2.458) | <0.001 | 1.668(1.353,2.057) | <0.001 | 1.306(1.037,1.645) | 0.023 | ||
| 女性 | ||||||||
| MHR | 36.791(20.816,65.025) | <0.001 | 9.120(4.976,16.714) | <0.001 | 6.073(2.984,12.358) | <0.001 | ||
| MHR四分位数 | ||||||||
| Q1 | 1.000 | - | 1.000 | - | 1.000 | - | ||
| Q2 | 1.401(1.119,1.753) | 0.003 | 1.234(0.981,1.552) | 0.072 | 1.206(0.946,1.537) | 0.130 | ||
| Q3 | 1.792(1.457,2.203) | <0.001 | 1.344(1.085,1.664) | 0.007 | 1.297(1.032,1.631) | 0.026 | ||
| Q4 | 2.954(2.418,3.610) | <0.001 | 1.903(1.542,2.348) | <0.001 | 1.683(1.329,2.130) | <0.001 | ||
| [1] | 王靖宇,常宝成. 高尿酸血症/痛风流行病学特点及危险因素[J]. 国际内分泌代谢杂志,2016,36(2):78-81,88. DOI:10.3760/cma.j.issn.1673-4157.2016.02.002. |
| [2] | LIU R, HAN C, WU D,et al. Prevalence of hyperuricemia and gout in mainland China from 2000 to 2014:a systematic review and meta-analysis[J]. Biomed Res Int,2015,2015:762820. DOI:10.1155/2015/762820. |
| [3] | 中华医学会内分泌学分会. 中国高尿酸血症与痛风诊疗指南(2019)[J]. 中华内分泌代谢杂志,2020,36(1):1-13. DOI:10.3760/cma.j.issn.1000-6699.2020.01.001. |
| [4] | 高尿酸血症相关疾病诊疗多学科共识专家组. 中国高尿酸血症相关疾病诊疗多学科专家共识[J]. 中华内科杂志,2017,56(3):235-248. DOI:10.3760/cma.j.issn.0578-1426.2017.03.021. |
| [5] | LUIS-RODRÍGUEZ D, DONATE-CORREA J, MARTÍN-NÚÑEZ E,et al. Serum urate is related to subclinical inflammation in asymptomatic hyperuricaemia[J]. Rheumatology:Oxford,2021,60(1):371-379. DOI:10.1093/rheumatology/keaa425. |
| [6] | WANG H Y, SHI W R, YI X,et al. Assessing the performance of monocyte to high-density lipoprotein ratio for predicting ischemic stroke:insights from a population-based Chinese cohort[J]. Lipids Heal Dis,2019,18(1):127. DOI:10.1186/s12944-019-1076-6. |
| [7] | SHI W R, WANG H Y, CHEN S,et al. The impact of monocyte to high-density lipoprotein ratio on reduced renal function:insights from a large population[J]. Biomark Med,2019,13(9):773-783. DOI:10.2217/bmm-2018-0406. |
| [8] | ZHANG Y, LI S, GUO Y L,et al. Is monocyte to HDL ratio superior to monocyte count in predicting the cardiovascular outcomes:evidence from a large cohort of Chinese patients undergoing coronary angiography[J]. Ann Med,2016,48(5):305-312. DOI:10.3109/07853890.2016.1168935. |
| [9] | FAN J G, WEI L, ZHUANG H,et al. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018,China)[J]. J Dig Dis,2019,20(4):163-173. DOI:10.1111/1751-2980.12685. |
| [10] | ZHANG W Z. Intensified,optimized and standardized management of Chinese patients with hypertension:comments on "2018 Chinese Guidelines for Prevention and Treatment of Hypertension" [J]. J Geriatr Cardiol,2019,16(3):178-181. DOI:10.11909/j.issn.1671-5411.2019.03.013. |
| [11] | JUNG S W, KIM S M, KIM Y G,et al. Uric acid and inflammation in kidney disease[J]. Am J Physiol Ren Physiol,2020,318(6):F1327-1340. DOI:10.1152/ajprenal.00272.2019. |
| [12] | LU W J, XU Y Z, SHAO X N,et al. Uric acid produces an inflammatory response through activation of NF-κB in the hypothalamus:implications for the pathogenesis of metabolic disorders[J]. Sci Rep,2015,5:12144. DOI:10.1038/srep12144. |
| [13] | TOMIYAMA H, SHIINA K, VLACHOPOULOS C,et al. Involvement of arterial stiffness and inflammation in hyperuricemia-related development of hypertension[J]. Hypertension,2018,72(3):739-745. DOI:10.1161/HYPERTENSIONAHA.118.11390. |
| [14] | KUNDI, GOK M, KIZILTUNC E,et al. Relation between monocyte to high-density lipoprotein cholesterol ratio with presence and severity of isolated coronary artery ectasia[J]. Am J Cardiol,2015,116(11):1685-1689. DOI:10.1016/j.amjcard.2015.08.036. |
| [15] | AÇIKGÖZ S K, AÇIKGÖZ E, SENSOY B,et al. Monocyte to high-density lipoprotein cholesterol ratio is predictive of in-hospital and five-year mortality in ST-segment elevation myocardial infarction[J]. Cardiol J,2016,23(5):505-512. DOI:10.5603/CJ.a2016.0026. |
| [16] | MURPHY A J, WOOLLARD K J, HOANG A,et al. High-density lipoprotein reduces the human monocyte inflammatory response[J]. Arterioscler Thromb Vasc Biol,2008,28(11):2071-2077. DOI:10.1161/ATVBAHA.108.168690. |
| [17] | GHATTAS A, GRIFFITHS H R, DEVITT A,et al. Monocytes in coronary artery disease and atherosclerosis:where are we now?[J]. J Am Coll Cardiol,2013,62(17):1541-1551. DOI:10.1016/j.jacc.2013.07.043. |
| [18] | KRYCHTIUK K A, KASTL S P, HOFBAUER S L,et al. Monocyte subset distribution in patients with stable atherosclerosis and elevated levels of lipoprotein(a)[J]. J Clin Lipidol,2015,9(4):533-541. DOI:10.1016/j.jacl.2015.04.005. |
| [19] | MURPHY A J, WOOLLARD K J, HOANG A,et al. High-density lipoprotein reduces the human monocyte inflammatory response[J]. Arterioscler Thromb Vasc Biol,2008,28(11):2071-2077. DOI:10.1161/ATVBAHA.108.168690. |
| [20] | PARTHASARATHY S, BARNETT J, FONG L G. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein[J]. Biochim Biophys Acta,1990,1044(2):275-283. DOI:10.1016/0005-2760(90)90314-n. |
| [21] | ZHANG L, WAN Q L, ZHOU Y M,et al. Age-related and gender-stratified differences in the association between high triglyceride and risk of hyperuricemia[J]. Lipids Health Dis,2019,18(1):147. DOI:10.1186/s12944-019-1077-5. |
| [22] | YU X L, SHU L, SHEN X M,et al. Gender difference on the relationship between hyperuricemia and nonalcoholic fatty liver disease among Chinese:an observational study[J]. Medicine (Baltimore),2017,96(39):e8164. DOI:10.1097/MD.0000000000008164. |
| [23] | WALLACE I R, MCKINLEY M C, BELL P M,et al. Sex hormone binding globulin and insulin resistance[J]. Clin Endocrinol:Oxf,2013,78(3):321-329. DOI:10.1111/cen.12086. |
| [1] | HE Yang, YANG Rong, SHEN Can, YI Shanye, LIU Lidi, ZHAO Qian, WAN Zhi, LIAO Xiaoyang. Progress in Research on the Trajectory of Frailty and Its Influencing Factors [J]. Chinese General Practice, 2026, 29(30): 4372-4378. |
| [2] | JIANG Huajie, ZHUO Lin, LI Xinyue, JIN Rui, MA Yue, CUI Jingqiu, WANG Xiuying. Related Factors and Preventive Measures of Hyperuricemia in Elderly Men [J]. Chinese General Practice, 2026, 29(27): 3915-3923. |
| [3] | ZHANG Fan, CHANG Jianhua, YANG Juan, QIAO Hui, XIE Yongxin. The Prevalence Trend and Association Rules of Chronic Disease Comorbidity among Rural Residents in Ningxia Hui Autonomous Region [J]. Chinese General Practice, 2026, 29(27): 3956-3968. |
| [4] | LIU Zhenyu, WANG Wendong, YAO Qing, WANG Jiangmin, CAO Wendong. Analysis of Prevalence and Influencing Factors of Cardiovascular-kidney-metabolic Syndrome among Adults in Haidian District, Beijing [J]. Chinese General Practice, 2026, 29(27): 3969-3975. |
| [5] | XUE Cuirong, WEI Wei, WU Renyuan, XUE Yaqin, XU Huijiang, LYU Weijiang, JIANG Dandan. Prevalence and Management Status of Chronic Kidney Disease in Hypertensive and Type 2 Diabetic Populations: a Community-based Cross-sectional Study [J]. Chinese General Practice, 2026, 29(25): 3650-3654. |
| [6] | ZHANG Xuechao, QI Qi, WU Xinyu, HAN Quanle, LI Lei, DENG Jie, LI Cangtuo, YUE Bocheng, WU Shouling, LI Kangbo. Association between the Atherogenic Index of Plasma and New-onset Chronic Kidney Disease [J]. Chinese General Practice, 2026, 29(24): 3440-3446. |
| [7] | WANG Rui, LUO Shuoming, YANG Liang, WANG Peng, ZHAO Yang, WANG Qi, ZHOU Zhiguang. Diabetes Prevalence among Older Adults in China: a Systematic Review and Meta-analysis [J]. Chinese General Practice, 2026, 29(24): 3500-3508. |
| [8] | WANG Xinliang, ZOU Nannan, CHEN Nana, WANG Xin. Analysis of Clinical Characteristics and Prognostic Risk Factors in Patients with Pulmonary Mucormycosis Complicated with Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(22): 3154-3161. |
| [9] | AN Yanhong, WANG Shidong, LI Xiaoran, GUO Jiayang, WANG Zhe, SHA Peilin, MENG Yijun, LI Xiaoxuan, SHI Xue, YU Zexing, XIAO Yonghua. Study on Risk Factors and Nomogram Prediction Model for Diabetic Kidney Disease: Based on Contrast-enhanced Ultrasound Technology [J]. Chinese General Practice, 2026, 29(21): 2995-3003. |
| [10] | SONG Zhenzhen, CHEN Yang, WANG Jiwen, LIU Huishan, SHEN Simeng, SUN Ying, CHEN Xing. Study of Maternal Risk Factors Associated with Neonatal Asphyxia in Late Preterm and Term Infants [J]. Chinese General Practice, 2026, 29(20): 2874-2878. |
| [11] | YANG Xiaofeng, LI Xianwen, WU Yanfeng, ZHANG Qian, CHEN Juan, ZHAO Fengjiao. Association of Serum Vascular Endothelial Cadherin Levels with the Risk of Post-stroke Cognitive Impairment in Patients with Acute Ischemic Stroke [J]. Chinese General Practice, 2026, 29(20): 2867-2873. |
| [12] | ZHAO Huili, LU Lina, ZHUO Ya, WANG Xin. Clinical Characteristics and Risk Factors for Recurrence of Cryptogenic Organizing Pneumonia [J]. Chinese General Practice, 2026, 29(19): 2648-2655. |
| [13] | TANG Lijuan, QI Qi, ZHANG Fan, GAO Yifu, CAO Yajing, YUE Fujuan, GAO Jinchai, LIU Xiaoli. Characterisation of the Prevalence of Overweight/Obesity among Residents Aged 18-44 Years in Hebei Province in 2013 and 2020 [J]. Chinese General Practice, 2026, 29(19): 2695-2704. |
| [14] | YU Shan, CHE Yajie, SUBIYINUER· Maimaiti, GUO Kaiyang, FENG Xingxing, YAN Ping. A Comparative Study on the Current Situation and Influencing Factors of Subjective Cognitive Decline among Urban and Rural Elderly People in Xinjiang [J]. Chinese General Practice, 2026, 29(16): 2227-2233. |
| [15] | ZHEN Rui, GU Xufang, GAO Shengwei, ZHANG Bowen, REN Zhenjuan, YANG Ruixuan. Burden of Cardiovascular Diseases Attributable to Metabolic Risk Factors in China 1990—2021 and Projected Trends from 2022 to 2035 [J]. Chinese General Practice, 2026, 29(15): 2077-2083. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||